Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Mar;17(5):501-503.
doi: 10.1080/17568919.2025.2463311. Epub 2025 Feb 5.

Refinement of MEK inhibitors

Ankit Kumar Singh  1   2 , Adarsh Kumar  1 , Harshwardhan Singh  1 , Amita Verma  2 , Pradeep Kumar  1
Affiliations
Editorial

Refinement of MEK inhibitors

Ankit Kumar Singh et al. Future Med Chem. 2025 Mar.
No abstract available

Keywords: MAPK; MEK inhibitors; cancer; melanoma.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

References

    1. Hendrikse C, Theelen P, Van Der Ploeg P, et al. The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2023;171:83–94. doi: 10.1016/j.ygyno.2023.01.038 - DOI - PubMed
    1. Singh AK, Sonawane P, Kumar A, et al. Challenges and opportunities in the crusade of BRAF inhibitors: from 2002 to 2022. ACS Omega. 2023;8(31):27819–27844. doi: 10.1021/acsomega.3c00332 - DOI - PMC - PubMed
    1. Ram T, Singh AK, Kumar A, et al. MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives. RSC Med Chem. 2023;14:1837–1857. doi: 10.1039/D3MD00145H - DOI - PMC - PubMed
    1. Kwong AJ, Scheidt KA.. Non-‘classical’meks: a review of MEK3–7 inhibitors. Bioorg Med Chem Lett. 2020;30(13):127203. doi: 10.1016/j.bmcl.2020.127203 - DOI - PMC - PubMed
    1. Kwong AJ, Pham TN, Oelschlager HE, et al. Rational design, optimization, and biological evaluation of novel MEK4 inhibitors against pancreatic adenocarcinoma. ACS Med Chem Lett. 2021;12(10):1559–1567. doi: 10.1021/acsmedchemlett.1c00376 - DOI - PMC - PubMed

Publication types

LinkOut - more resources